Clinical trial
Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants
NCT00314041 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00314041 |
|---|---|
| Title | Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants |
| Official title | A Randomized, Double-blind, Controlled, Active Comparator, Phase II Study to Assess the Tolerance and Immunogenicity of Conjugate Meningococcal C (MnCC) Vaccine in Infants When Administered in Conjunction With Primary DTP/Hib Vaccination at 2, 3, and 4 Months of Age. |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Meningitis, Meningococcal |
| Intervention type | Biological |
| Interventions | Meningococcal C, DTP/Hib |
| Enrollment | 240 |
| Start date | Jun 1, 1997 |
| Primary completion | Apr 1, 1998 |
| Completion | Apr 1, 1998 |
| First posted | Apr 12, 2006 |
| Last update posted | Feb 21, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: